Sherman, K.E., Peters, M.G. and Thomas, D. (2017) Human Immunodeficiency Virus and Liver Disease: A Comprehensive Update. Hepatology Communications, 1, 987-1001.
https://doi.org/10.1002/hep4.1112

has been cited by the following article:

• TITLE: Effects of Hepatitis B Virus Co-Infection and Antiretroviral Therapy on Disease Progression among HIV Patients Treated at the Buea Regional Hospital, Southwest Region, Cameroon: A Case-Control Study

  AUTHORS: Henry Dilonga Meriki, Andinwoh Ngassa Betterdel, Kukwah Anthony Tufon, Peter Njouda Shitebongnju

  KEYWORDS: HIV/HBV Co-Infection, NVP-Based, EFV-Based, Antiretroviral Therapy, Fibrosis, Non-Invasive Markers (NIM)

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.10 No.9, September 23, 2022

  ABSTRACT: In the era of “test and treat”, when AIDS-defining events have been drastically reduced, chronic liver disease associated with viral hepatitis and antiretroviral therapy (ART) remains an important cause of non-AIDS morbidity and mortality among HIV-infected patients. Compared to the general population, HIV-infected patients are about 10-times at risk of hepatitis B virus infection. Additionally, several antiretroviral regimens are hepatotoxic. Therefore, effective monitoring and management of ART and HBV co-infection are essential to ending the AIDS epidemic and eliminating viral hepatitis by 2030. This was a hospital-based, matched (age and sex) case-control study. HIV patients (case patients) on ART for at least six months and “healthy” controls aged 18 years and older were enrolled. Blood samples were collected for immuno-hematologic indices and transaminases measurements. Data were presented as counts, percentages, median (IQR) and means (SD), and a p-value 1.5) and mild (0.6 - 1.5) liver fibrosis based on the APRI score was 0.5% and 8%, respectively. Significant fibrosis (>3.25) was 0.9%, while 18.4% had inconclusive fibrosis (1.45 - 3.25) based on the FIB-4 score. HIV/HBV co-infected patients had a higher occurrence of liver fibrosis (APRI: 0.5% vs FIB-4: 0.9%). Co-infections with HBV increase the risk of liver-related morbidity in HIV patients. Therefore, screening for serological markers of chronic HBV infection and hepatic transaminase levels in HIV patients remains crucial in the continuum of care.